Corvus Pharmaceuticals (CRVS) Earnings Date, Estimates & Call Transcripts $3.37 +0.02 (+0.60%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.44 +0.07 (+2.20%) As of 03/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Corvus Pharmaceuticals Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 5After Market ClosesEstimatedActual EPS (Mar. 25) -$0.18 Missed By -$0.06 Consensus EPS (Mar. 25) -$0.12 Corvus Pharmaceuticals announced Q4 2024 earnings on March 25, 2025, reporting an EPS of -$0.18, which missed analysts' consensus estimates of -$0.12 by $0.06. With a trailing EPS of -$0.93, Corvus Pharmaceuticals' earnings are expected to grow next year, from ($0.63) to ($0.49) per share. Conference CallConference Call TranscriptCRVS Upcoming EarningsCorvus Pharmaceuticals' next earnings date is estimated for Monday, May 5, 2025, based off prior year's reporting schedules. Get Corvus Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corvus Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCRVS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRVS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Corvus Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.10-$0.10-$0.10Q2 20251-$0.11-$0.11-$0.11Q3 20251-$0.11-$0.11-$0.11Q4 20251-$0.11-$0.11-$0.11FY 20254($0.43)($0.43)($0.43) Remove Ads Corvus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/5/2025(Estimated)-------3/25/2025Q4 2024-$0.12-$0.18 -$0.06-$0.18--8/6/2024Q2 2024-$0.12-$0.07+$0.05-$0.07--5/6/2024Q1 2024-$0.12-$0.12--$0.12--3/19/2024Q4 2023-$0.14-$0.14--$0.14--11/7/2023Q3 2023-$0.16-$0.12+$0.04-$0.12--8/8/2023Q2 2023-$0.14-$0.14--$0.14--5/8/2023Q1 2023--$0.17 -$0.17-$0.17--3/28/2023Q4 2022--$0.21 -$0.21-$0.21-- Corvus Pharmaceuticals Earnings - Frequently Asked Questions When is Corvus Pharmaceuticals's earnings date? Corvus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 5th, 2025 based off last year's report dates. Learn more on CRVS's earnings history. Did Corvus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Corvus Pharmaceuticals (NASDAQ:CRVS) missed the analysts' consensus estimate of ($0.12) by $0.06 with a reported earnings per share (EPS) of ($0.18). Learn more on analysts' earnings estimate vs. CRVS's actual earnings. How can I listen to Corvus Pharmaceuticals's earnings conference call? The conference call for Corvus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Corvus Pharmaceuticals's conference call transcript? The conference call transcript for Corvus Pharmaceuticals's latest earnings report can be read online. Read Transcript How much profit does Corvus Pharmaceuticals generate each year? Corvus Pharmaceuticals (NASDAQ:CRVS) has a recorded net income of -$27.03 million. CRVS has generated -$0.93 earnings per share over the last four quarters. What is Corvus Pharmaceuticals's EPS forecast for next year? Corvus Pharmaceuticals's earnings are expected to grow from ($0.63) per share to ($0.49) per share in the next year. More Earnings Resources from MarketBeat Related Companies ELVN Earnings MLYS Earnings NRIX Earnings VIR Earnings NTLA Earnings COLL Earnings RCUS Earnings RCKT Earnings XNCR Earnings ZYME Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Remove Ads This page (NASDAQ:CRVS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
